Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
Elizabeth Whittaker, MD1,2; Alasdair Bamford, MD3,4; Julia Kenny, MD5,6; et alMyrsini Kaforou, PhD2; Christine E. Jones, MD7; Priyen Shah, MD2; Padmanabhan Ramnarayan, MD1,8; Alain Fraisse, MD9; Owen Miller, MD10,11; Patrick Davies, MD12; Filip Kucera, MD13; Joe Brierley, MD14; Marilyn McDougall, MD6,15; Michael Carter, MD6,15; Adriana Tremoulet, MD16; Chisato Shimizu, MD16; Jethro Herberg, MD1,2; Jane C. Burns, MD16; Hermione Lyall, MD1; Michael Levin, MD2; for the PIMS-TS Study Group and EUCLIDS and PERFORM Consortia
Author Affiliations Article Information
JAMA. Published online June 8, 2020. doi:10.1001/jama.2020.10369
Abstract
Importance In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.
Objectives To describe the clinical and laboratory characteristics of hospitalized children who met criteria for the pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PIMS-TS) and compare these characteristics with other pediatric inflammatory disorders.
Design, Setting, and Participants Case series of 58 children from 8 hospitals in England admitted between March 23 and May 16, 2020, with persistent fever and laboratory evidence of inflammation meeting published definitions for PIMS-TS. The final date of follow-up was May 22, 2020. Clinical and laboratory characteristics were abstracted by medical record review, and were compared with clinical characteristics of patients with Kawasaki disease (KD) (n = 1132), KD shock syndrome (n = 45), and toxic shock syndrome (n = 37) who had been admitted to hospitals in Europe and the US from 2002 to 2019.
